Gilead Sciences Inc (GILD) Common Stock USD0.001
Sell:$107.87Buy:$107.88
$0.32
(0.30%)
0.46%- This stock can be held in a
Stocks and Shares ISA$0.32
(0.30%)$0.32
(0.30%)Company Information
About this company
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. It operates in more than 35 countries worldwide.
Key people
Key facts
- EPICGILD
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS3755581036
- Market cap$133.35bn
- Employees17,600
- Shares in issue1.25bn
- ExchangeNASDAQ
- IndexS&P 500, NASDAQ 100 Index, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.